--- title: "Wells Fargo & Company Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $45.00" description: "Wells Fargo & Company has lowered its price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) from $65.00 to $45.00 while maintaining an \"overweight\" rating. This suggests a potential upside of 128.1" type: "news" locale: "en" url: "https://longbridge.com/en/news/271110841.md" published_at: "2025-12-30T13:30:18.000Z" --- # Wells Fargo & Company Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $45.00 > Wells Fargo & Company has lowered its price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) from $65.00 to $45.00 while maintaining an "overweight" rating. This suggests a potential upside of 128.19% from the current price. Other firms have also adjusted their targets, with Truist Financial setting a new target of $90.00 and TD Cowen at $75.00. The stock opened at $19.72, with a 52-week range of $18.41 to $46.50. The company reported a quarterly EPS of ($1.81), missing estimates, and has a market cap of $1.90 billion. Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its target price reduced by stock analysts at Wells Fargo & Company from $65.00 to $45.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an "overweight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's target price suggests a potential upside of 128.19% from the company's current price. - Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential Several other research firms also recently weighed in on RARE. Truist Financial lowered their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a "buy" rating on the stock in a report on Wednesday, November 5th. TD Cowen lowered their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 5th. Barclays cut their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, November 24th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $77.57. **Read Our Latest Stock Analysis on Ultragenyx Pharmaceutical** ## Ultragenyx Pharmaceutical Stock Performance Shares of NASDAQ:RARE opened at $19.72 on Tuesday. Ultragenyx Pharmaceutical has a 52-week low of $18.41 and a 52-week high of $46.50. The business's 50 day simple moving average is $33.66 and its two-hundred day simple moving average is $32.11. The firm has a market cap of $1.90 billion, a P/E ratio of -3.32 and a beta of 0.16. Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The firm had revenue of $159.93 million for the quarter, compared to the consensus estimate of $167.42 million. During the same quarter in the prior year, the firm earned ($1.40) EPS. The company's revenue was up 14.6% compared to the same quarter last year. On average, equities analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year. ## Insider Transactions at Ultragenyx Pharmaceutical In other news, CFO Howard Horn sold 7,942 shares of the firm's stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the completion of the sale, the chief financial officer directly owned 98,227 shares of the company's stock, valued at $3,095,132.77. This trade represents a 7.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.50% of the stock is owned by company insiders. ## Institutional Trading of Ultragenyx Pharmaceutical A number of large investors have recently added to or reduced their stakes in RARE. Northern Trust Corp grew its position in shares of Ultragenyx Pharmaceutical by 7.5% during the 1st quarter. Northern Trust Corp now owns 568,389 shares of the biopharmaceutical company's stock valued at $20,581,000 after acquiring an additional 39,424 shares during the period. Comerica Bank lifted its stake in Ultragenyx Pharmaceutical by 464.2% in the first quarter. Comerica Bank now owns 7,352 shares of the biopharmaceutical company's stock valued at $266,000 after purchasing an additional 6,049 shares during the last quarter. Magnetar Financial LLC grew its holdings in Ultragenyx Pharmaceutical by 64.4% during the first quarter. Magnetar Financial LLC now owns 11,147 shares of the biopharmaceutical company's stock valued at $404,000 after purchasing an additional 4,368 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Ultragenyx Pharmaceutical in the first quarter worth $4,400,000. Finally, PDT Partners LLC raised its stake in shares of Ultragenyx Pharmaceutical by 114.7% in the first quarter. PDT Partners LLC now owns 104,921 shares of the biopharmaceutical company's stock valued at $3,799,000 after buying an additional 56,062 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock. ## Ultragenyx Pharmaceutical News Roundup Here are the key news stories impacting Ultragenyx Pharmaceutical this week: - Neutral Sentiment: Company press release: Ultragenyx announced Orbit and Cosmic Phase 3 top-line results; neither trial achieved the primary endpoint of reduced annualized clinical fracture rate. Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta - Neutral Sentiment: Trading halt: Nasdaq temporarily halted RARE trading for "news pending" ahead of the top-line announcement, then resumed as the company disclosed results. - Negative Sentiment: Late‑stage failure coverage: Multiple outlets report setrusumab did not meet primary endpoints, confirming the drug will not deliver the fracture‑reduction benefit tested in these studies. Ultragenyx's bone disease drug fails late-stage trials (Reuters) - Negative Sentiment: Market reaction: Reports show the stock plunged sharply after the announcements as investors repriced the company for the lost commercial opportunity and increased execution risk. Ultragenyx stock plunges after setrusumab fails in Phase 3 OI trials - Negative Sentiment: Cost and structure impact: Ultragenyx signaled "significant" cutbacks and restructuring after the failure; local reporting estimates the market value decline exceeded $1 billion. That raises near‑term execution and workforce risk. Ultragenyx vows 'significant' cutbacks as failed study wipes more than $1 billion from Novato biotech's market value - Negative Sentiment: Broader reporting and analysis: Coverage highlights the failure to improve fracture rates and describes overall "mixed" secondary data but emphasizes the primary endpoints were not met — limiting regulatory/commercial prospects. Ultragenyx Shares Slide as Bone Disorder Drug Misses Trial Endpoints ## About Ultragenyx Pharmaceutical (Get Free Report) Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval. The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders. ## Featured Stories - Five stocks we like better than Ultragenyx Pharmaceutical - Wall Street Stockpicker Names #1 Stock of 2026 - ALERT: Drop these 5 stocks before January 2026! - How a Family Trust May Be Able To Help Preserve Your Wealth - Your “birthright claim” just got activated - Chilling warning from legendary investor *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now? Before you consider Ultragenyx Pharmaceutical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list. While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [RARE.US - Ultragenyx Pharma](https://longbridge.com/en/quote/RARE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Syndax 制药｜8-K：2025 财年 Q4 营收 68.73 百万美元超过预期 | | [Link](https://longbridge.com/en/news/277094758.md) | | Syndax 制药｜10-K：2025 财年营收 1.72 亿美元超过预期 | | [Link](https://longbridge.com/en/news/277095834.md) | | Xenon 制药｜8-K：2025 财年营收 7.5 百万美元 | | [Link](https://longbridge.com/en/news/277094902.md) | | BioCryst 制药｜8-K：2025 财年营收 8.75 亿美元超过预期 | | [Link](https://longbridge.com/en/news/277039171.md) | | ANI 制药｜8-K：2025 财年 Q4 营收 2.47 亿美元超过预期 | | [Link](https://longbridge.com/en/news/277195599.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.